Động vật đã được điều trị với cơ thể 2 mg / kg cân nặng paclitaxel trong xe (động vật kiểm soát được điều trị bằng xe một mình) hai giờ sau khi bị thương và hàng ngày cho bốn ngày tiếp theo. | 376 Antisense approach these devices is pressure-driven delivery that causes additional vessel damage and low efficacy. Viral vectors or different lipid carriers may increase the efficacy of delivery. Fibrin meshwork is an alternative vehicle for sustained release of antisense a factor that may be important in the case of stent implantation. Polymer-coated stents have been used successfully to deliver micromolar concentrations of c-myc antisense PMO into the vessel wall 74 Fig. 2 . Zhang et al. 75 reported effective local delivery of c-myc antisense ODN by gelatin-coated platinum-ipidium stents in rabbits. These experiences showed that ultimate success will require polymers that are capable of rapid elution of the oligonucleotide with minimal capacity to inflame or otherwise cause additional injury to the vessel wall. Perfluorobutane gas microbubbles with a coating of dextrose and albumin efficiently bind antisense oligomers 76 . These to IQ- m particles bind to sites of vascular injury. Furthermore perfluorobutane gas is an effective cell membrane fluidizer The potential advantages of microbubble carrier delivery include minimal additional vessel injury from delivery no resident polymer to degrade leading to eventual inflammation rapid bolus delivery and the high likelihood of repeated delivery. In addition the potential for perfluorocarbon gas microbubble carriers PGMC to deliver to vessel regions both proximal and distal to stents in vessels suggests this mode of delivery will serve as an excellent adjuvant to a variety of catheter and coated-stent delivery techniques. First clinical experience of antisense therapy in the treatment of restenosis The clinical applicability of antisense technology remains limited by a relative lack of specificity slow uptake across the cell membrane and rapid degradation of oligonucleotides. Promising results emerged from the PREVENT trial 77 which showed efficacy of ex vivo gene therapy of human vascular bypass grafts with .